Objective: To study expression of membrane receptors of interleukin-2 (CD25) on the peripheral blood lymphocytes (PBL) of patients with colorectal cancer and its clinical significance. Methods: CD25 percentages (CD25%...Objective: To study expression of membrane receptors of interleukin-2 (CD25) on the peripheral blood lymphocytes (PBL) of patients with colorectal cancer and its clinical significance. Methods: CD25 percentages (CD25%) in PBL of 105 colorectal cancer patients before operation and 100 normal individuals were examined by flow cytometer, and the results were clinically and pathologically analyzed. Results: The mean of CD25% in PBL of the normal individuals was 17.24±5.33, it was significantly lower (P<0.01) than that of the colon cancer patients (21.29±7.95) or rectal cancer patients (21.62±6.11). In contrast to the normal individuals, the means of CD25% in PBL in ulcer type (20.53±6.50) or protruded type (21.56±6.16) colorectal cancer patients were notably elevated (P<0.01). The significant difference (P<0.01) of means of CD25% in PBL was observed between the normal individuals and patients with less than 4 cm mass (22.10±5.43) or 4cm–8cm mass (20.90±6.96). The significant difference (P<0.05) of means of CD25% in PBL was also observed between the normal individuals and patients with greater than 8 cm mass (21.56±5.41). The mean of CD25% in PBL in patients with well differentiation colorectal cancer was 22.20±5.50, it was significantly higher than that in normal individuals (P<0.05). The means of CD25% in PBL in patients with middle or poor differentiation colorectal cancer were 21.30±6.89 and 22.15±5.71 respectively, they were obviously higher than that in normal individuals (P<0.01). The significant difference (P<0.01) of means of CD25% in PBL was present between the colorectal cancer patients without metastatic lymph nodes (22.06±6.90) and normal individuals. The significant difference (P<0.05) of means of CD25% in PBL was present between the colorectal cancer patients with metastatic lymph nodes (20.73±6.40) and normal individuals. The means of CD25% in PBL in colorectal cancer patients in various clinic stages were significantly higher than that in the health subjects (P<0.01). The significant difference (P<0.01) of means of CD25% in PBL was present between the patients whose ages were equal to or less than 60 (21.00±5.76) and normal individuals in the same age group. The significant difference (P<0.05) of means of CD25% in PBL was also present between the patients whose ages were greater than 60 (22.54±7.75) and normal individuals in the same age group. The significant difference (P<0.01) of means of CD25% in PBL was present between the male patients (22.55±7.05) and normal men. The significant difference (P<0.05) of means of CD25% in PBL was also present between the female patients (20.09±5.48) and normal women. Conclusion: The mean of CD25% in PBL of colorectal cancer patients was significantly higher than that in health subjects. Abnormally elevated CD25% were correlative with site of tumor growth, macropathology type of tumor, the degree of tumor differentiation, clinical stage and patient’s age and sex. It may be helpful to detect CD25% in PBL of colorectal cancer patients before operation for diagnosis, immune treatment and judging prognosis.展开更多
Day 100 prognostic factors post-autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) to predict clinical outcomes in diffuse large B-cell lymphoma (DLBCL) patients have not been studied. Thus,...Day 100 prognostic factors post-autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) to predict clinical outcomes in diffuse large B-cell lymphoma (DLBCL) patients have not been studied. Thus, we retrospectively examined if day 100 absolute monocyte/lymphocyte prognostic score (AMLPS-100) affects clinical outcomes by landmark analysis from day 100 post-APBHSCT in DLBCL. Only DLBCL patients in complete remission at day 100 post-APBHSCT were evaluated. From 2000 to 2007, 134 consecutive DLBCL patients are qualified for the study. Patients with a day 100 absolute monocyte count (AMC-100) ≥ 630 cells/μL and day 100 absolute lymphocyte count (ALC-100) ≤ 1000 cells/μL experienced inferior overall survival (OS) and progression free survival (PFS). On multivariate analysis, the AMC-100 and ALC-100 remained independent predictors of OS and PFS. Combining both values into the AMLPS-100, the 5-year OS rates for low, intermediate, and high AMLPS-100 risk groups were 94% (95% CI, 83.0% - 98.1%), 70% (95% CI, 58.6% - 80.1%), and 13% (95% CI, 3.4% - 40.5%), respectively;and the 5-year PFS rates were 87% (95% CI, 74.0% - 94.1%), 68% (95% CI, 56.0% - 77.8%), and 13% (95% CI, 3.4% - 40.5%), respectively. The AMLPS-100 is a simple biomarker score that can stratify clinical outcomes from day 100 post-APBHSCT in DLBCL patients.展开更多
【目的】探讨系统性红斑狼疮(SLE)患者外周血单个核细胞(PBMCs)B细胞刺激因子(Blys)基因和蛋白在体外的表达及IL-10对其表达的影响。【方法】梯度密度离心法分离25例系统性红斑狼疮患者和20名女性健康志愿者外周血单个核细胞,分为2组,IL...【目的】探讨系统性红斑狼疮(SLE)患者外周血单个核细胞(PBMCs)B细胞刺激因子(Blys)基因和蛋白在体外的表达及IL-10对其表达的影响。【方法】梯度密度离心法分离25例系统性红斑狼疮患者和20名女性健康志愿者外周血单个核细胞,分为2组,IL-10(100ng/mL)组和培养基组(仅含RPMI1640培养基),分别于培养0、6、12、24、72h离心收集PBMCs,RT-PCR法检测刺激后0～24h细胞Blys mRNA表达,流式细胞仪和直接免疫荧光法检测72h膜结合型Blys蛋白表达。【结果】①系统性红斑狼疮患者外周血单个核细胞Blys mRNA和蛋白表达体外高于健康对照(P<0.001)。②IL-10显著增强健康对照和系统性红斑狼疮患者外周血单个核细胞Blys mRNA表达,12h作用最强(0.487±0.058 vs 0.251±0.050,P<0.001;0.638±0.084 vs 0.392±0.059,P<0.001)。③IL-10显著增强健康对照和系统性红斑狼疮患者外周血单个核细胞膜结合型Blys蛋白表达(FACs,4.53±0.71 vs 3.24±0.57,P<0.001;5.79±0.91 vs 4.55±0.83,P<0.001)。④直接免疫荧光法检测外周血单个核细胞膜结合型Blys蛋白显示,IL-10刺激后Blys表达增强。【结论】IL-10可上调系统性红斑狼疮患者外周血单个核细胞Blys基因和蛋白表达。展开更多
文摘Objective: To study expression of membrane receptors of interleukin-2 (CD25) on the peripheral blood lymphocytes (PBL) of patients with colorectal cancer and its clinical significance. Methods: CD25 percentages (CD25%) in PBL of 105 colorectal cancer patients before operation and 100 normal individuals were examined by flow cytometer, and the results were clinically and pathologically analyzed. Results: The mean of CD25% in PBL of the normal individuals was 17.24±5.33, it was significantly lower (P<0.01) than that of the colon cancer patients (21.29±7.95) or rectal cancer patients (21.62±6.11). In contrast to the normal individuals, the means of CD25% in PBL in ulcer type (20.53±6.50) or protruded type (21.56±6.16) colorectal cancer patients were notably elevated (P<0.01). The significant difference (P<0.01) of means of CD25% in PBL was observed between the normal individuals and patients with less than 4 cm mass (22.10±5.43) or 4cm–8cm mass (20.90±6.96). The significant difference (P<0.05) of means of CD25% in PBL was also observed between the normal individuals and patients with greater than 8 cm mass (21.56±5.41). The mean of CD25% in PBL in patients with well differentiation colorectal cancer was 22.20±5.50, it was significantly higher than that in normal individuals (P<0.05). The means of CD25% in PBL in patients with middle or poor differentiation colorectal cancer were 21.30±6.89 and 22.15±5.71 respectively, they were obviously higher than that in normal individuals (P<0.01). The significant difference (P<0.01) of means of CD25% in PBL was present between the colorectal cancer patients without metastatic lymph nodes (22.06±6.90) and normal individuals. The significant difference (P<0.05) of means of CD25% in PBL was present between the colorectal cancer patients with metastatic lymph nodes (20.73±6.40) and normal individuals. The means of CD25% in PBL in colorectal cancer patients in various clinic stages were significantly higher than that in the health subjects (P<0.01). The significant difference (P<0.01) of means of CD25% in PBL was present between the patients whose ages were equal to or less than 60 (21.00±5.76) and normal individuals in the same age group. The significant difference (P<0.05) of means of CD25% in PBL was also present between the patients whose ages were greater than 60 (22.54±7.75) and normal individuals in the same age group. The significant difference (P<0.01) of means of CD25% in PBL was present between the male patients (22.55±7.05) and normal men. The significant difference (P<0.05) of means of CD25% in PBL was also present between the female patients (20.09±5.48) and normal women. Conclusion: The mean of CD25% in PBL of colorectal cancer patients was significantly higher than that in health subjects. Abnormally elevated CD25% were correlative with site of tumor growth, macropathology type of tumor, the degree of tumor differentiation, clinical stage and patient’s age and sex. It may be helpful to detect CD25% in PBL of colorectal cancer patients before operation for diagnosis, immune treatment and judging prognosis.
文摘Day 100 prognostic factors post-autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) to predict clinical outcomes in diffuse large B-cell lymphoma (DLBCL) patients have not been studied. Thus, we retrospectively examined if day 100 absolute monocyte/lymphocyte prognostic score (AMLPS-100) affects clinical outcomes by landmark analysis from day 100 post-APBHSCT in DLBCL. Only DLBCL patients in complete remission at day 100 post-APBHSCT were evaluated. From 2000 to 2007, 134 consecutive DLBCL patients are qualified for the study. Patients with a day 100 absolute monocyte count (AMC-100) ≥ 630 cells/μL and day 100 absolute lymphocyte count (ALC-100) ≤ 1000 cells/μL experienced inferior overall survival (OS) and progression free survival (PFS). On multivariate analysis, the AMC-100 and ALC-100 remained independent predictors of OS and PFS. Combining both values into the AMLPS-100, the 5-year OS rates for low, intermediate, and high AMLPS-100 risk groups were 94% (95% CI, 83.0% - 98.1%), 70% (95% CI, 58.6% - 80.1%), and 13% (95% CI, 3.4% - 40.5%), respectively;and the 5-year PFS rates were 87% (95% CI, 74.0% - 94.1%), 68% (95% CI, 56.0% - 77.8%), and 13% (95% CI, 3.4% - 40.5%), respectively. The AMLPS-100 is a simple biomarker score that can stratify clinical outcomes from day 100 post-APBHSCT in DLBCL patients.
文摘【目的】探讨系统性红斑狼疮(SLE)患者外周血单个核细胞(PBMCs)B细胞刺激因子(Blys)基因和蛋白在体外的表达及IL-10对其表达的影响。【方法】梯度密度离心法分离25例系统性红斑狼疮患者和20名女性健康志愿者外周血单个核细胞,分为2组,IL-10(100ng/mL)组和培养基组(仅含RPMI1640培养基),分别于培养0、6、12、24、72h离心收集PBMCs,RT-PCR法检测刺激后0～24h细胞Blys mRNA表达,流式细胞仪和直接免疫荧光法检测72h膜结合型Blys蛋白表达。【结果】①系统性红斑狼疮患者外周血单个核细胞Blys mRNA和蛋白表达体外高于健康对照(P<0.001)。②IL-10显著增强健康对照和系统性红斑狼疮患者外周血单个核细胞Blys mRNA表达,12h作用最强(0.487±0.058 vs 0.251±0.050,P<0.001;0.638±0.084 vs 0.392±0.059,P<0.001)。③IL-10显著增强健康对照和系统性红斑狼疮患者外周血单个核细胞膜结合型Blys蛋白表达(FACs,4.53±0.71 vs 3.24±0.57,P<0.001;5.79±0.91 vs 4.55±0.83,P<0.001)。④直接免疫荧光法检测外周血单个核细胞膜结合型Blys蛋白显示,IL-10刺激后Blys表达增强。【结论】IL-10可上调系统性红斑狼疮患者外周血单个核细胞Blys基因和蛋白表达。
